Author:
Eom Ki-Seong,Min Woo-Sung,Kim Hee-Je,Cho Byung-Sik,Choi Su-Mi,Lee Dong-Gun,Lee Seok,Min Chang-Ki,Kim Yoo-Jin,Cho Seok-Goo,Lee Jong-Wook,Kim Chun-Choo
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology,General Medicine
Reference29 articles.
1. Robak T, Wrzesien-Kus A. The search for optimal treatment in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2002;43:281–91.
2. Davis CL, Rohatiner AZ, Lim J, et al. The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period. Br J Haematol. 1993;83:404–11.
3. Liso V, Iacopino P, Avvisati G, et al. Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first-line induction therapy: a GIMEMA study of 218 unselected consecutive patients. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. Leukemia. 1996;10:1443–52.
4. Vignetti M, Orsini E, Petti MC, et al. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: a single-centre experience. Ann Oncol. 1996;7:933–8.
5. Bassan R, Lerede T, Buelli M, et al. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia. Haematologica. 1998;83:422–7.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献